추천자료
[병리][병리학][독성병리][임상병리사][병리학자][외과병리학][비교병리학법][독성병리]병리와 병리학, 병리와 독성병리, 병리와 임상병리사, 병리와 병리학자 분석(병리, 병리학, 독성병리, 임상병리사, 병리학자)
[병리학] 병리학의 개요(세포적응과 세포손상, 세포손상의 원인, 염증과 치유)
병리학적 관점에서의 아토피 피부염의 치료와 스킨케어 방향에 관한 연구
가정폭력의 원인을 정신병리학적, 사회심리학적, 상호작용 혹은 체계이론, 사회문화적 이론으로 접근하여 설명
[보건의학]정신보건사회복지론 - 정신 병리학에 대하여
[사회문제의 이론적 관점] 사회문제를 설명하는 이론(사회병리학적 이론, 사회해체이론, 일탈이론, 낙인이론)
동물병리학 및 실습하기
가정폭력의 원인을 정신병리학적, 가정폭력의 원인을 정신병리학적, 사회심리학적, 상호작용 혹은 체계이론, 사회문화적 이론으로 접근하여 설명하시오
필기 정리-병리학
병리학개론남성생식기질환
소개글
[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis에 대한 자료입니다.
본문내용
Myelofibrosis
Myeloproliferative neoplasm(MPN)
조혈모세포의 비정상적인 증식으로 인한 질환군, 정상적인 성숙과정을 보이는 효율적 조혈로 말초혈액에서 혈구의 수적증가를 초래한다.
대부분 massive splenomegaly 동반함
Polycytehmia : 정상적인 적혈구 생산 조절기전(Physiologid stimuli)과는 무관하게 주로 적혈구 생산이 증가되는 MPN, JAK2 mutation 동반
Primary myelofibrosis : 주로 megakaryocytes와 granulocytes가 증식되는 MPN으로 골수의 reactive fibrosis와 골수외조혈(extramedullary hematopoiesis)이 특징인 질환
Essenstial Thrombocythemia : 주로 megakaryocytes가 지속적인 thrombocytosis large,mature megakaryocytes의 증가가 특징인 질환
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-1](http://images.happyhaksul.com/thumb/878/877877-0001.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-2](http://images.happyhaksul.com/thumb/878/877877-0002.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-3](http://images.happyhaksul.com/thumb/878/877877-0003.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-4](http://images.happyhaksul.com/thumb/878/877877-0004.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-5](http://images.happyhaksul.com/thumb/878/877877-0005.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-6](http://images.happyhaksul.com/thumb/878/877877-0006.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-7](http://images.happyhaksul.com/thumb/878/877877-0007.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-8](http://images.happyhaksul.com/thumb/878/877877-0008.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-9](http://images.happyhaksul.com/thumb/878/877877-0009.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-10](http://images.happyhaksul.com/thumb/878/877877-0010.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-11](http://images.happyhaksul.com/thumb/878/877877-0011.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-12](http://images.happyhaksul.com/thumb/878/877877-0012.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-13](http://images.happyhaksul.com/thumb/878/877877-0013.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-14](http://images.happyhaksul.com/thumb/878/877877-0014.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-15](http://images.happyhaksul.com/thumb/878/877877-0015.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-16](http://images.happyhaksul.com/thumb/878/877877-0016.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-17](http://images.happyhaksul.com/thumb/878/877877-0017.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-18](http://images.happyhaksul.com/thumb/878/877877-0018.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-19](http://images.happyhaksul.com/thumb/878/877877-0019.gif)
![[병리학] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis-20](http://images.happyhaksul.com/thumb/878/877877-0020.gif)
분야
pptx
